arrow
S

Sabine Merkelbach-Bruse

University of Cologne
H指数:55
被引数:9,625

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass)

GUIDANCE试验的原理与设计方案:一项多中心II期临床试验,旨在评估标准一线治疗(卡铂/顺铂、依托泊苷和度伐利尤单抗)后,对HRD阳性广泛期(ED)小细胞肺癌(SCLC)患者进行度伐利尤单抗和奥拉帕利维持治疗的疗效(AIO-TRK-0124/ass)

2026-09-010
PRE
Pitfalls in detecting MET exon 14 skipping variants by DNA- and RNA- based next generation sequencing technologies in a large real-world cohort and results of the first multinational EQA schemes

在大型真实世界队列中,通过基于DNA和RNA的下一代测序技术检测MET外显子14跳跃变异的陷阱及首个跨国EQA方案的初步结果

2026-06-040
PRE
AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer

人工智能驱动的空间细胞表型学增强非小细胞肺癌的风险分层

2025-11-030
OAAI
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma

CSF1R⁺髓系-单核细胞驱动侵袭性B细胞淋巴瘤中CAR-T细胞的耐药性

2025-06-120
OAAI
Assessment of p53 in Endometrial Carcinoma Biopsy and Corresponding Hysterectomy Cases in a Real-World Setting: Which Cases Need Molecular Work-Up?

评估真实世界背景下子宫内膜癌活检及对应子宫切除术病例中p53的情况:哪些病例需要进行分子检测?

CANCERS
IF4.4
2025-04-290
OA
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations [Eur J Cancer 207 (2024) 114158]
2024-12-010
OAAI
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations
2024-08-012
OAAI
AI-driven, mIF-based cell-omics reveals spatially resolved cell signature for outcome prediction in NSCLC patients
2024-03-220
PRE
TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading
2024-03-220
PRE
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancerdfinal results of the EUCROSS trial
2024-02-011
OAAI
TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading
2024-01-012
OA
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer
2023-11-013
OAAI